TP53 and cancer: Moreover, subgroup analysis, based on age, gender, tumor grade, TP53 mutation status, individual cancer stage, and nodal metastasis status suggested that CXCL2 was significantly upregulated in STAD tissues compared with normal tissues, and that CXCL2 is a promising a diagnostic biomarker for STAD.